Mass. startup gets $30M boost to advance gene regulators

04/12/2013 | American City Business Journals · Xconomy

A Series A funding round led by Arch Venture Partners and Flagship Ventures has brought in $30 million to Syros Pharmaceuticals, which is developing treatment techniques based on advanced genetic sequencing and insights into how proteins control genetic expression in stem cells. The Watertown, Mass.-based biotech startup will use the money to expedite the discovery and development of proteins it calls super enhancers.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC